Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Consulting agrmnt Director departure Appointed COO Appointed director
|
Organicell Regenerative Medicine, Inc. (BPSR)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/28/2023 |
PRE 14C
| Form PRE 14C - Other preliminary information statements: |
08/25/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
08/14/2023 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
08/09/2023 |
8-K
| Completion of Acquisition or Disposition of Assets Interactive Data |
08/01/2023 |
PRE 14C
| Form PRE 14C - Other preliminary information statements: |
07/26/2023 |
8-K
| Quarterly results |
07/11/2023 |
8-K
| Quarterly results |
07/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/30/2023 |
4
| Skycrest Holdings, LLC (10% Owner) has filed a Form 4 on Organicell Regenerative Medicine, Inc.
Txns:
| Bought 400,000 shares
@ $0.009, valued at
$3.6k
Bought 200,000 shares
@ $0.009, valued at
$1.8k
|
|
06/30/2023 |
4
| Leider Harry L. (CEO) has filed a Form 4 on Organicell Regenerative Medicine, Inc.
Txns:
| Bought 549,450 shares
@ $0.099, valued at
$54.4k
Bought 500,000 shares
@ $0.01, valued at
$5k
|
|
06/29/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
06/28/2023 |
4
| Skycrest Holdings, LLC (10% Owner) has filed a Form 4 on Organicell Regenerative Medicine, Inc.
Txns:
| Bought 800,000 shares
@ $0.009, valued at
$7.2k
|
|
06/16/2023 |
10-Q
| Quarterly Report for the period ended April 30, 2023 |
06/09/2023 |
3
| Golub Howard Lawrence (Executive Vice President & CSO) has filed a Form 3 on Organicell Regenerative Medicine, Inc. |
06/09/2023 |
3
| Leider Harry L. (CEO and Director) has filed a Form 3 on Organicell Regenerative Medicine, Inc. |
06/09/2023 |
8-K
| Other Events Interactive Data |
06/06/2023 |
8-K
| Investor presentation |
05/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
04/21/2023 |
8-K
| Quarterly results |
03/17/2023 |
10-Q
| Quarterly Report for the period ended January 31, 2023 |
03/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs:
|
"SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT , dated as of March 6, 2023, by and between ORGANICELL REGENERATIVE MEDICINE, INC., a Nevada corporation, with headquarters located at 3321 College Avenue, Suite 246, Davie, FL 33314 , and AJB CAPITAL INVESTMENTS, LLC, a Delaware limited liability company, with its address at 4700 Sheridan Street, Suite J, Hollywood, FL 33021 . WHEREAS: A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission under the Securities Act of 1933, as amended ; B. The Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions s...",
"Promissory Note made in favor of AJB Capital Investments",
"Warrant issued to AJB Capital Investments" |
|
01/30/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
12/30/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
12/23/2022 |
8-K
| Quarterly results |
12/16/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
12/01/2022 |
8-K
| Quarterly results |
11/25/2022 |
8-K
| Quarterly results |
11/21/2022 |
8-K
| Quarterly results |
11/03/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
11/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/27/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
10/25/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
10/20/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
10/17/2022 |
4
| Sinnreich Matthew Phillip (President and Acting CEO) has filed a Form 4 on Organicell Regenerative Medicine, Inc.
Txns:
| Sold 20,000 shares
@ $0.04, valued at
$800 |
|
|
|
|